Author:
Macheras Panos,Tsekouras Athanasios A.
Publisher
Springer International Publishing
Reference9 articles.
1. Food and Drug Administration, Code of Federal Regulations Title 21, 5 Subpart B - Procedures for Determining the Bioavailability or Bioequivalence of Drug Products. 1971. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?fr=320.21
2. Lovering EG, McGilveray IJ, McMillan I, Tostowaryk W (1975) Comparative bioavailabilities from truncated blood level curves. J Pharm Sci 64:1521–1524. https://doi.org/10.1002/jps.2600640921
3. Tsekouras AA, Macheras P (2021) Re-examining digoxin bioavailability after half a century: time for changes in the bioavailability concepts. Pharm Res 38:1635–1638. https://doi.org/10.1007/s11095-021-03121-w
4. Sanchez N, Sheiner LB, Halkin H, Melmon KL (1973) Pharmacokinetics of digoxin: interpreting bioavailability. Br Med J 4:132. https://doi.org/10.1136/bmj.4.5885.132
5. Center for Drug Evaluation and Research, Digoxin Bioequivalency Review 76268 (2002). https://www.accessdata.fda.gov/ drugsatfda_docs/anda/2002/76268_Digoxin_Bioeqr.pdf